Evidence map›Paper›PMID 21272602›Full record

ArticleVaccine2011

A novel retinoic acid, catechin hydrate and mustard oil-based emulsion for enhanced cytokine and antibody responses against multiple strains of HIV-1 following mucosal and systemic vaccinations.

Mingke Yu, Michael Vajdy

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mingke YuEpitoGenesis, Inc. 1810 North Broadway, Walnut Creek, CA 94596, USA.
Michael Vajdy
EpitoGenesis (United States) · US

Funding

Mucosal Immune-enhancing Delivery System for HIV vaccinesR43AI084690 · NIAID · EPITOGENESIS, INC. · PI VAJDY, MICHAEL SEJR · 2009 to 2010
$286k
NIAID NIH HHS 1R43AI084690-01NIAID NIH HHS R43 AI084690
6 · The paper itself

Abstract

Non-replicating protein- or DNA-based antigens generally require immune-enhancing adjuvants and delivery systems. It has been particularly difficult to raise antibodies against gp120 of HIV-1, which constitutes an important approach in HIV vaccine design. While almost all effort in adjuvant research has focused on mimicking the pathogens and the danger signals they engender in the host, relatively little effort has been spent on nutritive approaches. In this study, a new nutritive immune-enhancing delivery system (NIDS) composed of vitamin A, a polyphenol-flavonoid, catechin hydrate, and mustard oil was tested for its adjuvant effect in immune responses against the gp120 protein of HIV-1(CN54). Following a combination of two mucosal and two systemic vaccinations of mice, we found significant enhancement of both local and systemic antibodies as well as cytokine responses. These data have important implications for vaccine and adjuvant design against HIV-1 and other pathogens.

Indexed as

Adjuvants, ImmunologicAIDS VaccinesAnimalsCatechinCytokinesEmulsionsFemaleHIV AntibodiesHIV Envelope Protein gp120Immunization, SecondaryMiceMice, Inbred BALB CMustard PlantPlant OilsTretinoinVaccinationAdjuvants, ImmunologicAIDS VaccinesCatechinCytokinesEmulsionsgp120 protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp120mustard oilPlant OilsTretinoin

Identifiers

PMID21272602
PMCPMC3055955
OpenAlexW2043464011

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.